(Sharecast News) - Shares in AIM-listed RUA Life Sciences tumbled on Monday after the medical devices group reported weaker-than-expected trading at its French subsidiary Abiss, despite forecasting higher annual revenues and a return to profitability.
The company expects revenues of approximately £5.5m for the year ended 30 September, up around 8%...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE